MK-1026-003
Efficacy and Safety of Nemtabrutinib in Participants With Hematologic Malignancies
Recruiting
Trial purpose
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT04728893
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Chronic Lymphocytic Leukaemia, Hematologic Malignancies, Non-Hodgkins Lymphoma, Waldenstroms Macroglobulinaemia
Age Range
18+
Sex
Male/Female
About the trial
All patients who enroll in the trial will receive medication while on the study.
100% will receive nemtabrutinib
Current trial Phase
Phase 2
Tests the medicine or vaccine in approximately 100 to 500 participants. In the case of medicines, participants usually have the disease or condition the investigational medicine is designed to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 04-05-2021
- Estimated primary completion date 03-19-2027
- Estimated trial completion date 03-19-2027
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.